3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/EP2019/054217, filed Feb 20, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,484,537 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders Aelis Farma, Institut National de la Sante et de la Recherche Medicale (Inserm) and Universite de Bordeaux In force · High confidence UsedRemaining | Aelis Farma, Institut National de la Sante et de la Recherche Medicale (Inserm) and Universite de Bordeaux | In force | High confidence | ||
| US 12,447,159 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders Institut National de la Sante et de la Recherche Medicale (Inserm), Universite de Bordeaux and Aelis Farma In force · High confidence | Institut National de la Sante et de la Recherche Medicale (Inserm), Universite de Bordeaux and Aelis Farma | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.